Search Result

Results for "

Gout and hyperuricemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (2) Bcl-2 Family (2) Caspase (2) Endogenous Metabolite (4) GLUT (2) HSP (2) Interleukin Related (3) Isotope-Labeled Compounds (4) JNK (2) Keap1-Nrf2 (2) NF-κB (2) NOD-like Receptor (NLR) (1) OAT (3) Reference Standards (3) SOD (2) URAT1 (12) Xanthine Oxidase (20)
By Research Areas:	Cancer (9) Cardiovascular Disease (6) Infection (5) Inflammation/Immunology (13) Metabolic Disease (27) Neurological Disease (4)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Fat Mass and Obesity-associated Protein (FTO)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B1135

Benzbromarone 5+ Cited Publications	Xanthine Oxidase Apoptosis Interleukin Related Keap1-Nrf2 SOD Caspase Bcl-2 Family NF-κB JNK HSP	Metabolic Disease
Benzbromarone is an orally active anti-gout agent. Benzbromarone has anti-infammatory, anti-oxidative stress and nephroprotective effects. Benzbromarone can be used for the research of hyperuricemia and gout .

HY-147300

Puliginurad YL-90148	URAT1	Cardiovascular Disease Metabolic Disease
Puliginurad (YL-90148) is a potent urate transporter (URAT) inhibitor. Puliginurad can be used for hyperuricemia and gout research .

HY-N9959

Isoengeletin	Others	Metabolic Disease Inflammation/Immunology
Isoengeletin is a flavonoid that can be isolated from the roots of Smilax bockii warb. Isoengeletin can be used as an active compound for the research of psoriasis, hyperuricemia and gout .

HY-158056

URAT1/GLUT9-IN-1	GLUT URAT1	Metabolic Disease
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC₅₀=2.01 μM) and glucose transporter 9 (GLUT9) (IC₅₀=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .

HY-101439

JTT-552	URAT1	Others
JTT-552 is a compound targeting URAT1 with activity in inhibiting hyperuricemia and gout.

HY-160265

URAT1 inhibitor 9	URAT1	Inflammation/Immunology
URAT1 inhibitor 9 (Compound 24) is an URAT1 inhibitor that can be used in the study of gout or hyperuricemia .

HY-157306

HC-1310	URAT1	Metabolic Disease
HC-1310 URAT1 Inhibitor (Compound 83) is a potent URAT1 inhibitor and can be used for research on hyperuricemia and gout .

HY-B1135R

Benzbromarone (Standard)	Reference Standards Xanthine Oxidase Apoptosis Interleukin Related Keap1-Nrf2 SOD Caspase Bcl-2 Family NF-κB JNK HSP	Metabolic Disease
Benzbromarone (Standard) is the analytical standard of Benzbromarone. This product is intended for research and analytical applications. Benzbromarone is an orally active anti-gout agent. Benzbromarone has anti-infammatory, anti-oxidative stress and nephroprotective effects. Benzbromarone can be used for the research of hyperuricemia and gout .

HY-W104467

(+/-)-Epicatechin (+/-)-Epicatechol; (+/-)-epi-Catechin	Xanthine Oxidase	Metabolic Disease
(+/-)-Epicatechin is a xanthine oxidase inhibitor with an IC₅₀ of 982.14 μM, and can be found in Semen Plantaginis (Plantago seed). (+/-)-Epicatechin can be used in research on diseases such as hyperuricemia and gout .

HY-14268A

Febuxostat sodium TEI 6720 sodium; TMX 67 sodium	Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat (TEI 6720) sodium is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat sodium has the potential for the research of hyperuricemia and gout .

HY-14268

Febuxostat 10+ Cited Publications TEI 6720; TMX 67	Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-144303

Xanthine oxidase-IN-4	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-4 (compound 19a) is an orally active and potent xanthine oxidase (XO) inhibitor, with an IC₅₀ of 0.039 μM. Xanthine oxidase-IN-4 exhibits hypouricemic potency in potassium oxonate induced hyperuricemia rats. Xanthine oxidase-IN-4 can be used for hyperuricemia and gout research .

HY-114309

URAT1 inhibitor 1	URAT1	Inflammation/Immunology
URAT1 inhibitor 1 (1g) is a uric acid transporter 1 (URAT1) inhibitor, with an IC₅₀ of 32 nM. URAT1 inhibitor 1 has potential to treat hyperuricemia associated with gout .

HY-B0219S

Allopurinol-d2	Isotope-Labeled Compounds Xanthine Oxidase	Infection Inflammation/Immunology
Allopurinol-d₂ is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC₅₀ values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect .

HY-177070

Angexostat	Xanthine Oxidase	Inflammation/Immunology
Angexostat (Compound 2) is an inhibitor of xanthine oxidase. Angexostat exhibits high permeability. Angexostat inhibits CYP2C9 with an IC₅₀ of 18.1 μM. Angexostat can be studied in research for xanthine oxidase-related diseases such as hyperuricemia and gout .

HY-14268R

Febuxostat (Standard) TEI 6720 (Standard); TMX 67 (Standard)	Reference Standards Xanthine Oxidase	Cardiovascular Disease Metabolic Disease
Febuxostat (Standard) is the analytical standard of Febuxostat. This product is intended for research and analytical applications. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-14268S2

Febuxostat-d3 TEI 6720-d₃; TMX 67-d₃	Isotope-Labeled Compounds Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat-d₃ (TEI 6720-d₃) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-14268S3

Febuxostat-d5 TEI 6720-d₅; TMX 67-d₅	Isotope-Labeled Compounds Xanthine Oxidase	Cardiovascular Disease Metabolic Disease Cancer
Febuxostat-d₅ (TEI 6720-d₅) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-146273

Xanthine oxidase-IN-7	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-7 (compound1h) is a potent andorally active XO (xanthine oxidase) inhibitor with an IC₅₀ of 0.36 µM. Xanthine oxidase-IN-7 effectively reduces serum uric acid levels. Xanthine oxidase-IN-7 has the potential for the research of hyperuricemia and gout .

HY-111345

Epaminurad UR-1102; URC-102	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad is a uricosuric agent. Epaminurad can be used for gout and hyperuricemia research .

HY-111345A

Epaminurad hydrochloride UR-1102 hydrochloride; URC-102 hydrochloride	OAT URAT1	Metabolic Disease Inflammation/Immunology
Epaminurad (UR-1102) hydrochloride is an orally active, potent and selective URAT1 (urate transporter 1) inhibitor, with a K_i of 0.057 μM. Epaminurad hydrochloride quite modestly inhibits OAT1 and OAT3 (organic anion transporter). Epaminurad hydrochloride is a uricosuric agent. Epaminurad hydrochloride can be used for gout and hyperuricemia research .

HY-161514

Xanthine oxidase-IN-15	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-15 (Compound 6c) is a selective inhibitor of Xanthine oxidase (XO) (IC₅₀=0.13 μM). Xanthine oxidase-IN-15 inhibits XO catalysis by forming a stable interaction with the active site of XO. Xanthine oxidase-IN-15 is mainly used in the study of hyperuricemia and gout .

HY-P2921B

Uricase, Arthrobacter globiformis Uox, Arthrobacter globiformis	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-P2921D

Uricase, candida utilis	Endogenous Metabolite	Metabolic Disease
Uricase, candida utilis is a peroxidase enzyme. It catalyzes the oxidation of uric acid, converting it into the soluble product allantoin. Uricase, candida utilis can be used for the determination of uric acid levels in serum. A deficiency of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, candida utilis can be utilized in research on gout and hyperuricemia .

HY-175309

URAT1-IN-14	URAT1	Metabolic Disease
URAT1-IN-14 is a potent and orally active Urate transporter 1 (URAT1) inhibitor. URAT1-IN-14 inhibits the human URAT1 in HEK293 cells with an IC₅₀ of 0.72 μM. URAT1-IN-14 exhibits low cytotoxic in Hep-G2 cells. URAT1-IN-14 shows urate-lowering effect in hyperuricemia mouse models. URAT1-IN-14 can be used for the study of hyperuricemia and gout .

HY-139585

Tigulixostat LC350189	Xanthine Oxidase	Metabolic Disease
Tigulixostat (LC350189) is an orally active non-purine selective xanthine oxidase inhibitor. Tigulixostat has IC₅₀ values of 0.003 µM and 0.073 µM in bovine milk and rat plasma, respectively. Tigulixostat can effectively reduce serum uric acid levels and can be used in the research of gout and hyperuricemia .

HY-P2921A

Uricase, Bacillus fastidious Uox, Bacillus fastidious	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-P2921C

Uricase (Recombinant) Uox (Recombinant)	Endogenous Metabolite	Metabolic Disease
Uricase, Arthrobacter globiformis is a peroxidase enzyme responsible for catalyzing the oxidative reaction of uric acid, converting it into the soluble product allantoin. Uricase, Arthrobacter globiformis can be used for the determination of uric acid levels in serum. The lack of uricase in mammals can lead to kidney diseases caused by the accumulation of uric acid. Uricase, Arthrobacter globiformis can be utilized in research on gout and hyperuricemia .

HY-B0219A

Allopurinol sodium Maximum Cited Publications 12 Publications Verification	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol sodium is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol sodium can be used in the research of hyperuricemia and gout. Allopurinol sodium decreases the expression of HIF-1α and HIF-2α protein. Allopurinol sodium shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-B0219

Allopurinol Maximum Cited Publications 12 Publications Verification	Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-173231

hURAT1 inhibitor 2	URAT1	Metabolic Disease
hURAT1 inhibitor 2 (Compound 5) is an inhibitor of hURAT1 (uric acid transporter 1, SLC22A12) with an IC₅₀ of 18 nM. hURAT1 inhibitor 2 also has a certain inhibitory effect on OATP1B1, with an IC₅₀ value of 0.73 μM. hURAT1 inhibitor 2 can be used in the research of diseases related to abnormal uric acid metabolism, such as hyperuricemia and gout .

HY-108844

Rasburicase	Xanthine Oxidase	Metabolic Disease Cancer
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .

HY-175303

Xanthine oxidase-IN-17	Xanthine Oxidase	Metabolic Disease
Xanthine oxidase-IN-17 is a potent xanthine oxidase (XOD) inhibitor with an IC₅₀ of 298 nM and a K_i of 167 nM. Xanthine oxidase-IN-17 decreases the formation of O_₂ ^⁻ radical by inhibiting the catalytic activity of XOD to diminish the production of uric acid. Xanthine oxidase-IN-17 shows no cytotoxicity in AML-12 hepatocytes, while suppressing uric acid production. Xanthine oxidase-IN-17 can be used for the studies of hyperuricemia and subsequently to gout .

HY-143906

URAT1 inhibitor 2	URAT1	Inflammation/Immunology
URAT1 inhibitor 2 is an orally active and potent URAT1 and CYP isozyme inhibitor, with IC₅₀ values of 1.36 μM, 16.97 μM, 5.22 μM for URAT1-mediated ¹⁴C-UA uptake, CYP1A2 and CYP2C9, respectively. URAT1 inhibitor 2 is a promising agent candidate in the study of hyperuricemia and gout .

HY-B0219R

Allopurinol (Standard)	Reference Standards Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

HY-175645

NLRP3/URAT1-IN-1	NOD-like Receptor (NLR) URAT1 Interleukin Related OAT GLUT	Metabolic Disease Inflammation/Immunology
NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC₅₀ = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC₅₀ of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .

HY-B0219S1

Allopurinol-13C,15N2	Isotope-Labeled Compounds Xanthine Oxidase	Infection Neurological Disease Inflammation/Immunology Cancer
Allopurinol- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N9959

Isoengeletin	Smilax biumbellata T. Koyama Flavonoids Smilacaceae Flavonones Source classification Plants	Others
Isoengeletin is a flavonoid that can be isolated from the roots of Smilax bockii warb. Isoengeletin can be used as an active compound for the research of psoriasis, hyperuricemia and gout .

HY-108844

Rasburicase	Natural Products Classification of Application Fields Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	Xanthine Oxidase
Rasburicase is a recombinant form of urate oxidase that works by catalyzing the oxidation of uric acid to allantoin, which has a higher solubility. Rasburicase specifically degrades uric acid, rapidly lowers blood uric acid levels, and improves inflammation and kidney damage caused by uric acid crystal deposition. Rasburicase can effectively lower uric acid and prevent uric acid nephropathy, and is used in the study of severe hyperuricemia associated with tumor lysis syndrome (TLS) and refractory gout .

HY-W104467

(+/-)-Epicatechin (+/-)-Epicatechol; (+/-)-epi-Catechin	Malvaceae Flavonoids Flavanols Source classification Phenols Polyphenols Plants Scaphium wallichii	Xanthine Oxidase
(+/-)-Epicatechin is a xanthine oxidase inhibitor with an IC₅₀ of 982.14 μM, and can be found in Semen Plantaginis (Plantago seed). (+/-)-Epicatechin can be used in research on diseases such as hyperuricemia and gout .

Cat. No.	Product Name	Chemical Structure

HY-B0219S

Allopurinol-d2
Allopurinol-d₂ is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC₅₀ values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect .

HY-14268S2

Febuxostat-d3
Febuxostat-d₃ (TEI 6720-d₃) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-14268S3

Febuxostat-d5
Febuxostat-d₅ (TEI 6720-d₅) is deuterium labeled Febuxostat. Febuxostat (TEI 6720) is a potent, selective and non-purine xanthine oxidase (XO) inhibitor with a K_i value of 0.6 nM. Febuxostat has the potential for the research of hyperuricemia and gout .

HY-B0219S1

Allopurinol-13C,15N2
Allopurinol- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

Allopurinol-13C,15N2

Allopurinol- ¹³C, ¹⁵N₂ is the ¹³C- and ¹⁵N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC₅₀ value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks